DJIA 17,550.69 -47.51 -0.27%
NASDAQ 5,105.55 -9.84 -0.19%
S&P 500 2,093.32 -4.72 -0.22%
market minute promo

Alnylam Pharmaceuticals (NASDAQ: ALNY)

125.88 -0.34 (-0.27%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALNY $125.88 -0.27%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $126.73
Previous Close $126.22
Daily Range $123.73 - $128.59
52-Week Range $53.29 - $140.00
Market Cap $10.6B
P/E Ratio -71.31
Dividend (Yield) $0.00 (0.0%)
Volume 429,793
Average Daily Volume 679,976
Current FY EPS -$2.96

Sector

Healthcare

Industry

Drug Makers

Alnylam Pharmaceuticals (ALNY) Description

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes. Website: http://www.alnylam.com/

News & Commentary

How Rare-Disease Drugmaker Alexion Pharmaceuticals Found Its Groove in June

A trio of positive events sends rare disease-drug developer Alexion shooting higher by a double-digit percentage. Can the good times continue?

3 Stocks Pushing The Drugs Industry Downward

First Week of March 2016 Options Trading For Alnylam Pharmaceuticals (ALNY)

An Assessment Of Celgene's Deal For Receptos

Health Care Sector Update for 07/20/2015: HRTX, ALNY, STEM

Alnylam Initiates Phase 3 Open Label Extension Study with Patisiran, an Investigational RNAi Therape

Alnylam Initiates Phase 3 Open Label Extension Study with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR Amyloidosis)

Today's Stocks Driving Success For The Drugs Industry

Use Options For a Chance To Buy ALNY at a 37% Discount

Benitec And Bluebird Bio, Gene Therapy Coming Of Age?

5 Biotech Stocks On Deck With The FDA

See More ALNY News...

ALNY's Top Competitors

ALNY $125.88 (-0.27%)
Current stock: ALNY
AMGN $174.80 (-0.45%)
Current stock: AMGN
GILD $118.87 (-0.61%)
Current stock: GILD
BIIB $330.38 (1.85%)
Current stock: BIIB